Drug Profile
TAK 639
Alternative Names: SHP 639Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Shire
- Developer Takeda
- Class Antiglaucomas; Eye disorder therapies; Natriuretic agents; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma; Ocular hypertension
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Glaucoma in USA (Ophthalmic, Drops)
- 28 Jun 2020 No recent reports of development identified for phase-I development in Ocular-hypertension in USA (Ophthalmic, Drops)
- 08 Jan 2019 Shire has been acquired and merged into Takeda